---
schema_version: "secwatch.filing_event.v1"
accession: "0001157523-22-000251"
form_type: "8-K"
ticker: "EWTX"
cik: "0001710072"
company_name: "Edgewise Therapeutics, Inc."
filed_at: "2022-02-24T23:59:59+00:00"
generated_at: "2026-06-27T04:55:08.770484+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Edgewise reports Q4 2021 net loss $12.7M, cash $281M; EDG-5506 Phase 1b positive

## Summary
- Net loss Q4 2021 $12.7M ($0.26/share); full year net loss $42.8M ($1.14/share).
- Cash, equivalents & marketable securities $281M as of Dec 31, 2021.
- Phase 1b EDG-5506 in BMD: CK reduced 71%, TNNI2 reduced 83%; well-tolerated.
- Phase 2 trials planned: BMD in H1 2022, DMD in H2 2022; ARCH open-label study ongoing.
- R&D expenses $32.2M in 2021 (vs $15.0M in 2020); G&A $11.0M (vs $2.2M).

## SEC filing metadata
- accession: 0001157523-22-000251
- form_type: 8-K
- ticker: EWTX
- cik: 0001710072
- company_name: Edgewise Therapeutics, Inc.
- filed_at: 2022-02-24T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1710072/000115752322000251/0001157523-22-000251-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1710072/000115752322000251/a52584668.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001157523-22-000251
- JSON: https://secwatch.observer/filing/0001157523-22-000251.json
- Plain text: https://secwatch.observer/filing/0001157523-22-000251.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.